Cargando…
Hodgkin Lymphoma on Hemodialysis Successfully Treated with Extended Courses of Brentuximab Vedotin
Chemotherapy for hemodialysis (HD) patients is a challenging situation because HD patients are generally frail, and the pharmacokinetics and pharmacodynamics of most chemotherapeutics in HD patients are unknown. We report a classical Hodgkin lymphoma (cHL) patient successfully treated with 34 course...
Autores principales: | Uchimura, Ayana, Yasuda, Hajime, Ando, Jun, Ota, Yasunori, Sasaki, Makoto, Takaku, Tomoiku, Tsukune, Yutaka, Tsutsui, Miyuki, Edahiro, Yoko, Watanabe, Naoki, Ochiai, Tomonori, Komatsu, Norio, Ando, Miki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8958608/ https://www.ncbi.nlm.nih.gov/pubmed/35431857 http://dx.doi.org/10.1159/000523823 |
Ejemplares similares
-
Bosutinib-induced lung injury: a report of two cases and literature review
por: Watanabe, Naoki, et al.
Publicado: (2022) -
Brentuximab vedotin for relapsed or refractory Hodgkin’s lymphoma
por: Chen, Runzhe, et al.
Publicado: (2015) -
Brentuximab Vedotin Treatment for Primary Refractory Hodgkin Lymphoma
por: Wu, Hung-Bo, et al.
Publicado: (2013) -
Desensitization of Brentuximab Vedotin in a Patient with Hodgkin Lymphoma
por: Khalid, Sidra, et al.
Publicado: (2018) -
The Evolving Role of Brentuximab Vedotin in Classical Hodgkin Lymphoma
por: Lai, Catherine, et al.
Publicado: (2019)